Teligent Recalls Five Additional Lots of Lidocaine Topical Solution

Dextenza Approved to Treat Itching in the Eye Caused by Allergies
October 11, 2021
Verzenio Receives New Indication for High-Risk Early Breast Cancer
October 13, 2021
Dextenza Approved to Treat Itching in the Eye Caused by Allergies
October 11, 2021
Verzenio Receives New Indication for High-Risk Early Breast Cancer
October 13, 2021

October 12, 2021 – Teligent Pharma has recalled five lots of Lidocaine HCl Topical Solution 4%, 50mL, in a screw cap glass bottle. The affected lidocaine was found to be super potent. This recall is in addition to a September 2021 recall of one lot of Lidocaine HCl Topical Solution 4%, 50mL, also due to super potency.

  • There is no impact to members through Benecard Central Fill.
  • The recalled product is indicated to provide pain relief for the mouth, nose, and throat.
  • A drug is super potent when it’s stronger than it should be. Using super potent lidocaine may lead to potentially severe or fatal local anesthetic systemic toxicity, depending on the patient and duration of treatment. As of the recall date, Teligent had not received reports of adverse events related to the affected product.
  • Teligent Pharma advises individuals in possession of the recalled lidocaine solution to discontinue use and dispose of the product immediately.
  • Questions about the recall can be directed to Teligent Pharma at 1-856-697-1441 (press *) or Medical@teligent.com. Patients who have experienced any problems that may be related to use of the affected lidocaine should contact their healthcare provider.
  • The full recall notice, including affected lot numbers, can be viewed on the U.S. FDA's website.